NLRP3 Protein Inhibitors Pipeline Research Report 2024: Therapeutic Assessment of 25+ Drugs by Product Type, Stage, Route of Administration, and Molecule Type [Yahoo! Finance]
Monte Rosa Therapeutics, Inc. (GLUE)
Company Research
Source: Yahoo! Finance
The report assesses the therapeutic potential of these drugs by product type, stage, route of administration, and molecule type. It highlights the emerging drugs, including Diacerein, HT6184, and VENT 02, which are in various stages of clinical development for the treatment of conditions such as Epidermolysis bullosa and Inflammatory Pain. The report also provides information on key players, collaborations, and licensing activities in the NLRP3 Protein Inhibitors therapeutics space. Dublin, Nov. 21, 2024 (GLOBE NEWSWIRE) -- The "NLRP3 Protein Inhibitors - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering. The report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in NLRP3 Protein Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It furt
Show less
Read more
Impact Snapshot
Event Time:
GLUE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GLUE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GLUE alerts
High impacting Monte Rosa Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
GLUE
News
- NLRP3 Protein Inhibitors Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight | DelveInsight [Yahoo! Finance]Yahoo! Finance
- Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare ConferenceGlobeNewswire
- Owning 47% shares,institutional owners seem interested in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), [Yahoo! Finance]Yahoo! Finance
- Monte Rosa Therapeutics (GLUE) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswire
GLUE
Earnings
- 8/8/24 - Beat
GLUE
Sec Filings
- 11/14/24 - Form SC
- 11/12/24 - Form SC
- 11/7/24 - Form 10-Q
- GLUE's page on the SEC website